University of Groningen Molecular characterization of tumor vascular phenotype and pharmacology of antiangiogenic therapy Langenkamp, Elise IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below. Document Version Publisher's PDF, also known as Version of record Publication date: 2010 Link to publication in University of Groningen/UMCG research database Citation for published version (APA): Langenkamp, E. (2010). Molecular characterization of tumor vascular phenotype and pharmacology of antiangiogenic therapy Groningen: s.n. Copyright Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons). Take-down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim. Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum. Download date: 26-07-2017
Appendix Curriculum Vitae List of publications
Appendices CURRICULUM VITAE Elise Langenkamp werd geboren op 26 januari 1982 te Hoogeveen. Na het behalen van het VWO diploma aan de Openbare Scholengemeenschap De Groene Driehoek te Hoogeveen in 2000, begon zij met de opleiding Farmaceutische Wetenschappen aan de Rijksuniversiteit te Groningen. In 2003 rondde zij deze opleiding cum laude af met een Bachelor diploma, waarna zij haar studie aan de RUG vervolgde met de Top Master opleiding Medical Pharmaceutical Drug Innovation. Tijdens haar Master opleiding werkte zij aan twee onderzoeksprojecten van elk zes maanden bij de afdeling Farmacokinetiek Drug Delivery en de afdeling Moleculaire Virologie. In 2005 rondde ze deze Masteropleiding cum laude af. In het kader van deze Top Masteropleiding heeft ze onder begeleiding van Prof. dr. Ingrid (Grietje) Molema een voorstel voor een AiO-project geschreven, welke werd gehonoreerd door de onderzoeksschool GUIDE. Na eerst drie maanden een taalcursus Spaans te hebben gevolgd in Salamanca en Granada in Spanje, begon ze in januari 2006 als promovenda op het bovengenoemde project bij de Afdeling Pathologie en Medische Biologie van het UMCG in Groningen. Hier verrichtte zij onderzoek naar het moleculaire gedrag van tumorbloedvaten tijdens tumorgroei en de effecten hierop van behandeling met antiangiogene therapie. Als onderdeel van dit project, werkte ze vanaf januari tot mei 2009 in het laboratorium van Dr. Brad St.Croix in het NIH National Cancer Institute in Frederick, Maryland, Verenigde Staten. De resultaten van het promotieonderzoek staan beschreven in dit proefschrift. Vanaf januari 2011 zal Elise gaan werken als postdoctoral fellow in het laboratorium van Dr. Anna Dimberg en Dr. Lena Claesson-Welsh aan de Universiteit van Uppsala in Zweden. Elise Langenkamp was born on January 26, 1982, in Hoogeveen, The Netherlands. After graduating from highschool in 2000, she started to study Pharmaceutical Sciences at the University of Groningen and obtained her Bachelor s degree cum laude in 2003. She continued with the Top Master program Medical and Pharmaceutical Drug Innovation at the University of Groningen, during which she worked on two research projects of six months each at the Department of Pharmacokinetics Drug Delivery and the Department of Molecular Virology. In the final stage of this Master program, she wrote under supervision of Prof. dr. Ingrid (Grietje) Molema a proposal for a PhD project, that was funded by the Graduate School GUIDE. After obtaining her Master s degree cum laude in 2005, she followed a Spanish language course for three months in Salamanca and Granada, Spain. In January 2006, she started working as a PhD student on the above mentioned project at the Department of Pathology Medical Biology, University Medical Center Groningen. Her work focussed on creating a better understanding of the molecular behavior of the tumor vasculature during tumor growth, and the changes therein in response to antiangiogenic therapy. As a part of this project, she worked for four months in the laboratory of Dr. Brad St.Croix in the NIH National Cancer Institute at Frederick, Maryland, USA. The results of her PhD research are presented in this dissertation. In January 2011, Elise will start as a postdoctoral fellow in the laboratory of Dr. Anna Dimberg and Dr. Lena Claesson-Welsh at the University of Uppsala, Sweden. 184
Curriculum Vitae List of publications LIST OF PUBLICATIONS Articles Langenkamp E and Molema G: Microvascular endothelial cell heterogeneity: General concepts and pharmacological consequences for antiangiogenic therapy of cancer. Cell Tissue Res 2009; 335: 205-222. Hellebrekers DM, Melotte V, Viré E, Langenkamp E, Molema G, Fuks F, Herman JG, Van Criekinge W, Griffioen AW, van Engeland M: Identification of epigenetically silenced genes in tumor endothelial cells. Cancer Res 2007; 67: 4138-4148 de Graaf IA, de Kanter R, de Jager MH, Camacho R, Langenkamp E, van de Kerkhof EG, Groothuis GM: Empirical validation of a rat in vitro organ slice model as a tool for in vivo clearance prediction. Drug Metab Dispos 2006; 34: 591-599. Presentations on (inter)national meetings Kloster Seeon Meeting on Angiogenesis 2010, Seeon, Germany. VEGFR2 inhibition in Lewis Lung Carcinoma induces vascular stabilization in vivo and concomitant loss of VEGFR2 protein. (poster presentation) Keystone Conference on Angiogenesis in Health and Disease 2010, Keystone CO, USA. VEGFR2 inhibition in Lewis Lung Carcinoma induces loss of VEGFR2 protein and a shift in endothelial gene expression towards vascular stabilization. (poster presentation) Annual meeting of the Dutch Endothelial Cell Biology Society and the Dutch Society for Microcirculation Vascular Biology 2010, Biezenmortel, NL. Pharmacologic inhibition of VEGFR2 in vivo results in loss of VEGFR2 protein and a shift in tumor endothelial gene expression towards vascular stabilization. (oral presentation) ESH Euroconference on Angiogenesis 2008, Paris, France. Angiogenic gene expression in B16 melanoma; kinetics environmental dynamics. (poster presentation) Annual meeting of the Dutch Society for Microcirculation Vascular Biology 2007, Ermelo, NL. Angiogenic gene expression in B16 melanoma; kinetics environmental dynamics. (oral presentation) International Meeting on Angiogenesis 2007, Amsterdam, NL. Heterogeneous expression of angiogenic genes in B16 melanoma. (oral presentation) Funding and awards Graduate School GUIDE Annual Meeting 2010. Award for best poster. KWF Kankerbestrijding 2009. Travel grant for 4-month research visit to the lab of Dr. B. St.Croix, NIH National Cancer Institute, Frederick MD, USA. Graduate School GUIDE/MPDI Top Master program 2005. Funding for PhD study. 185
186